Loading stock…

Inhibrx Biosciences, Inc. (INBX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Inhibrx Biosciences, Inc.

INBXMarket cap $1.37BPrice $93.4

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops antibody-based therapies targeting rare and aggressive cancers, betting on multi-specific biologics engineered to outsmart tumors' escape routes. Its lead candidate targets a protein found in nearly all cancer types, aiming for precision where chemo can't reach.

In Bastion Portfolios?

52W Return+151%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-0%3

Revenue Forecast

Rev CAGR (1y)+75%10

Rev CAGR (3y)+353%10

Rev CAGR (5y)+207%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Marginna–

Net Income Marginna–

Free Cash Flow Marginna–

Debt

Net Debt/EBITDA-0.410

Efficiency

ROE-403%1

ROA-75%1

Earnings Stability22

GEAR+VERY WEAK12

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BVna–

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-9.6%1

Dividend Yieldna–

Momentum

Short term

1 month return-18%1

3 month return-4%5

YTD return+18%7

Mid term

Price vs 52wHigh60%2

1 year return+178%10

Long term

3 year return+571%10

5 year return+571%10

Risk Shield

Price Risk

Beta1.32

Volatility106%1

Free Cash Flow

Free Cash Flow Marginna–

Free Cash Flow Yield-9.6%1

Quality

ROCE-85%1

Earnings Stability22

Net Debt/EBITDA-0.410

02Growth

Is it actually growing, and how fast?

INBXInhibrx Biosciences

Revenue FY25$1M

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+75%10

Revenue, next 3Y, CAGR+353%10

Revenue, next 5Y, CAGR+207%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue is set to grow 353%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 353%/yr from here.

The runway holds up: revenue is set to grow 207%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE59 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return-4%5

YTD return+18%7

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return+178%10

3-year return+571%10

5-year return+571%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +571% over three years and +571% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming so far this year (+18%).

WATCH

It's up 178% over the past year, but 40% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over three months (-4%).

WEAKNESSES

The stock is underperforming over the past month (-18%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Inhibrx Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

INBXInhibrx Biosciences

Revenue FY25$1M

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+75%10

Revenue, next 3Y, CAGR+353%10

Revenue, next 5Y, CAGR+207%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue is set to grow 353%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 353%/yr from here.

The runway holds up: revenue is set to grow 207%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE59 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return-4%5

YTD return+18%7

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return+178%10

3-year return+571%10

5-year return+571%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +571% over three years and +571% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming so far this year (+18%).

WATCH

It's up 178% over the past year, but 40% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over three months (-4%).

WEAKNESSES

The stock is underperforming over the past month (-18%).

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout. The one thing to watch: the stock is underperforming over the past month.

04Value

Are you paying a fair price for it?

Stop guessing on Inhibrx Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community